Sept 17 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH® ANNOUNCES INVESTIGATOR SPONSORED MULTIPLE MYELOMA STUDY COMBINING REOLYSIN® AND NIVOLUMAB (OPDIVO®) WITH STANDARD OF CARE
* ONCOLYTICS BIOTECH INC - FINAL STUDY DESIGN AND OTHER DETAILS WILL BE ANNOUNCED UPON ENROLLMENT OF FIRST PATIENT, EXPECTED BEFORE END OF 2018